Danaher Q3 2021 Earnings Report
Key Takeaways
Danaher Corporation reported a strong third quarter in 2021, with revenues increasing by 23.0% year-over-year to $7.2 billion and non-GAAP core revenue growth of 20.5%. Net earnings were $1.2 billion, or $1.54 per diluted common share, a 33.0% increase year-over-year. Non-GAAP adjusted diluted net earnings per common share were $2.39, representing a 39.0% increase over the comparable 2020 period.
Revenues increased 23.0% year-over-year to $7.2 billion.
Non-GAAP core revenue growth was 20.5%.
Net earnings were $1.2 billion, or $1.54 per diluted common share, a 33.0% increase year-over-year.
Non-GAAP adjusted diluted net earnings per common share were $2.39, a 39.0% increase year-over-year.
Danaher
Danaher
Forward Guidance
For the fourth quarter 2021, the Company anticipates that non-GAAP core revenue growth will be in the low-to-mid teens percent range. For the full year 2021, the Company now anticipates that the non-GAAP core revenue growth rate including Cytiva will be more than 20%.
Positive Outlook
- Non-GAAP core revenue growth expected in the low-to-mid teens percent range for Q4 2021.
- Full year 2021 non-GAAP core revenue growth rate including Cytiva expected to be more than 20%.
- Continued investment for growth across businesses.
- Expanding production capacity.
- Accelerating innovation initiatives.
Challenges Ahead
- Highly uncertain and unpredictable severity, magnitude and duration of the COVID-19 pandemic.
- Impact of debt obligations on operations and liquidity.
- Deterioration of or instability in the economy, the markets served and the financial markets.
- Uncertainties relating to U.S. laws or policies, including potential changes in U.S. trade policies and tariffs.
- Contractions or growth rates and cyclicality of markets served.